CSIMarket Company Name, Ticker, Competitors, else..
 
Can fite Biopharma Ltd   (NYSE: CANF)
 
Price: $2.2300 $-0.12 -5.106%
Day's High: $2.3499999046325684 Week Perf: -29.87 %
Day's Low: $ 2.23 30 Day Perf: -37.36 %
Volume (M): 183,300 52 Wk High: $ 13.40
Volume (M$): $ 0 52 Wk Avg: $5.23
Open: $2.34 52 Wk Low: $2.23



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 2
 Employees 5
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Can Fite Biopharma Ltd is a biopharmaceutical company that specializes in the development of small molecule drugs for the treatment of inflammatory and liver diseases, as well as cancer. The company focuses on combining modern science and traditional medicine to create innovative therapeutics. Can Fite Biopharma Ltd has a strong pipeline of drug candidates and aims to bring effective and safe treatment options to patients worldwide.


   Company Address: 26 Ben Gurion Street Ramat Gan 5257346
   Company Phone Number: (3) 924-1114   Stock Exchange / Ticker: NYSE CANF


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Announcement

Strategic Capital Raise Can-Fite BioPharma Secures $3 Million Through Registered Direct Offering of American Deposita...

Published Tue, Apr 15 2025 8:29 AM UTC

In a significant move to bolster its financial resources, Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a leading biotechnology entity specialising in pioneering small-molecule drugs for the treatment of oncological and inflammatory diseases, has announced the successful execution of definitive agreements pursuant to a registered direct offering. The offering, ...
Announcement

Breaking Genetic Boundaries Can-Fites Bold Step into Lowe Syndrome Treatment

Published Wed, Mar 19 2025 1:24 PM UTC

In a significant move that could reshape the landscape of rare disease treatment, Can-Fite Biopharma Ltd. has announced plans to initiate a Phase II clinical trial aimed at addressing Lowe Syndrome, a rare genetic disorder primarily affecting the eyes and brain. The study will focus on the therapeutic potential of Piclidenoson, an innovative candidate that may offer a new le...
Announcement

Regulatory Advances and Financial Realities Can-Fite BioPharmas Journey with Namodenoson

Published Wed, Oct 9 2024 11:00 AM UTC

In a significant advancement for pancreatic cancer treatment, Can-Fite BioPharma Ltd. has announced that its investigational oncology drug candidate, Namodenoson, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA). This designation is crucial for companies developing therapies for rare diseases, particularly in the context of aggressive m...
Announcement

Can-Fite Biopharma From Loss to Opportunity with $325M Veterinary Licensing Agreement,

Published Tue, Sep 24 2024 11:00 AM UTC

Can-Fite Biopharma: Turning a Loss into a $325 Million Opportunity with Veterinary Licensing AgreementIn the ever-evolving landscape of biotechnology, few stories emerge with the potential to reshape a company s fortunes like that of Can-Fite Biopharma Ltd. This Israeli biopharmaceutical company is poised for a significant turnaround after a notable partnership with Vetbiol...
Announcement

RAMAT GAN, Israel August 8, 2024 Can-Fite BioPharma Ltd., a growing player in the biotechnology sec...

Published Thu, Aug 8 2024 11:01 PM UTC

Can-Fite BioPharma Secures $5 Million Through Warrant Exercise: A Strategic Move for Oncology and Inflammatory Disease Drug Development RAMAT GAN, Israel August 8, 2024 Can-Fite BioPharma Ltd., a growing player in the biotechnology sector focused on developing innovative treatments for oncological and inflammatory diseases, has announced a significant financial maneuve...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 9.06
Price to Sales (Expected) -
Price to Book 0.66
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.82
Working Capital Ratio 3.09
Leverage Ratio (MRQ) 0.54
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -5.97 $
Revenues (TTM) 0.25 $
Cash Flow (TTM) -
Cash 5.19 $
Book Value 3.4 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 81,000
Net Income per Employee (TTM) -1,965,600
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.02

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -2456.79 %
Net Margin (MRQ) -2426.67 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Can Fite Biopharma Ltd's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.